Research programme: Zika virus vaccine - IMV
Latest Information Update: 31 Aug 2023
At a glance
- Originator Immunovaccine
- Developer IMV
- Class Synthetic vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Zika virus infection
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Zika virus infection (Prevention) in Canada (Parenteral) (imv website, August 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in Canada (Parenteral)
- 03 May 2018 Immunovaccine is now called IMV
Development Overview
Introduction
IMV (formerly Immunovaccine) was developing a viral vaccine, using its proprietary DepoVax™ technology, for the treatment of Zika virus infection. DepoVax™ is a patented vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a specific and sustained immune response with single-dose effectiveness. Preclinical development was underway in Canada.
In May 2018, Immunovaccine changed its name to IMV [1] .
As of August 2023, Research program was no longer listed on the company pipeline, therefore, it appears that development has been discontinued for Zika-virus-infection (Prevention) in Canada (Parenteral)(imv website, August 2023).
Company Agreements
In April 2016, Immunovaccine and Leidos entered into a collaborative agreement to develop a vaccine against Zika virus infections. Under the terms of the agreement, Leidos will discover antigen candidates, utilising its Virtual Pharmaceutical Development Program, and Immunovaccine will formulate best of them in its DepoVax™ delivery system for preclinical testing [2] .
Key Development Milestones
As of August 2023, Research program was no longer listed on the company pipeline, therefore, it appears that development has been discontinued for Zika-virus-infection (Prevention) in Canada (Parenteral)(imv website, August 2023).
Financing information
In June 2016, Immunovaccine reported closing of a bought deal private placement, from which net proceeds of $US8 002 500 will be used for progressing the development of the company's cancer and infectious vaccine candidates and also for general corporate and working capital purposes [3] .
Patent Information
The vaccine delivery formulation, DepoVax™, is patent protected [4] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Synthetic vaccines, Zika virus vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B (Viral Vaccines)
-
EPhMRA code
J7E (Viral Vaccines)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Zika virus infection | - | Prevention | Discontinued (Preclinical) | Canada | Parenteral / unspecified | IMV | 31 Aug 2023 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Immunovaccine | Originator | Canada |
| IMV | Owner | Canada |
| Leidos Holdings | Collaborator | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 31 Aug 2023 | Phase Change - Discontinued(Preclinical) | Discontinued - Preclinical for Zika virus infection (Prevention) in Canada (Parenteral) (imv website, August 2023) Updated 31 Aug 2023 |
| 28 Oct 2020 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in Canada (Parenteral) Updated 28 Oct 2020 |
| 03 May 2018 | Company Involvement | Immunovaccine is now called IMV Updated 17 May 2018 |
| 15 Sep 2016 | Phase Change - Preclinical | Preclinical trials in Zika virus infection (Prevention) in Canada (Parenteral) Updated 15 Sep 2016 |
| 07 Apr 2016 | Licensing Status | Immunovaccine and Leidos collaborate to develop Zika virus vaccine [2] Updated 19 Apr 2016 |
| 03 Mar 2016 | Phase Change | Early research in Zika virus infection in USA (Parenteral) Updated 19 Apr 2016 |
| 20 Jan 2015 | Patent Information | Immunovaccine has patent protection for DepoVax™ before January 2015 [4] Updated 11 Mar 2016 |
References
-
Immunovaccine Inc. Has Applied to List its Common Shares on Nasdaq,Announces Reverse Stock Split.
Media Release -
Immunovaccine and Leidos Join Forces to Develop a Zika Virus Vaccine Candidate.
Media Release -
Immunovaccine Announces Closing of $8 Million Bought Deal Private Placement Financing.
Media Release -
Health Canada Clears Immunovaccine to Conduct Phase I Clinical Trial of Respiratory Syncytial Virus (RSV) Vaccine.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG